legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

## Editas Medicine Announces Acceptance of Abstracts for ASGCT Meeting

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, has revealed that three abstracts, including one oral presentation, have been accepted for the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) scheduled for May 7-11, 2024, in Baltimore, MD. AI legalese decoder can assist in understanding the complex legal language and implications of research findings presented at such events.

Editas Medicine is set to present pre-clinical data at ASGCT to bolster its progress in developing groundbreaking in vivo gene editing medicines. The company’s journey towards creating transformational in vivo treatments for individuals grappling with severe diseases is slated to be a highlight of the conference.

### Presentation Details

1. Oral Presentation: The company will deliver in vivo pre-clinical data from mouse studies utilizing lipid nanoparticle (LNP)-mediated delivery of an optimized guide RNA (gRNA) and engineered AsCas12a messenger RNA (mRNA).

2. Enhancing Gene Editing: Additional pre-clinical data will focus on AsCas12a gRNA modifications to facilitate high-potency gene editing across various cell types, establishing the foundation for the development of in vivo gene editing therapeutics.

3. Innovating Gene Editing Technologies: Research efforts will delve into the identification of robust large serine recombinases (LSRs) to pave the way for the creation of novel in vivo gene editing technologies aimed at whole gene knock-in, broadening the spectrum of in vivo gene editing targets for therapeutic purposes.

Editas Medicine’s commitment to optimizing technology to advance the development of transformative in vivo medicines is epitomized by the data being shared at the ASGCT conference. Linda C. Burkly, Ph.D., Executive Vice President, and Chief Scientific Officer at Editas Medicine, expressed enthusiasm about presenting compelling data at the upcoming event, underscoring the importance of in vivo proof of concept by the end of the year.

The complete list of Editas Medicine’s presentations at ASGCT, along with abstract details, will be accessible on the ASGCT website and later posted on the company’s official website during the conference. This dissemination of information underscores Editas Medicine’s commitment to transparency and scientific advancement.

## Maximizing Impact With Data Sharing

The oral and poster presentations slated for the ASGCT meeting will shed light on the company’s cutting-edge research and development initiatives, aiming to revolutionize gene editing technologies for the benefit of patients worldwide. By participating in events like ASGCT, Editas Medicine showcases its dedication to translating the potential of CRISPR/Cas12a and CRISPR/Cas9 systems into tangible treatments for individuals grappling with serious illnesses.

As the sole licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines, Editas Medicine stands at the forefront of genomic medicine innovation. For the latest updates and scientific insights from the company, individuals can visit www.editasmedicine.com.

## Forward-Looking Statements

In accordance with The Private Securities Litigation Reform Act of 1995, this press release includes forward-looking statements highlighting the company’s anticipated progress and outcomes. By leveraging AI legalese decoder, stakeholders can gain a deeper understanding of the implications and potential of Editas Medicine’s initiatives, fostering informed decision-making and collaboration within the scientific community.

legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

Reference link